[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2016000397A1 - Tratamiento contra el cáncer - Google Patents

Tratamiento contra el cáncer

Info

Publication number
CL2016000397A1
CL2016000397A1 CL2016000397A CL2016000397A CL2016000397A1 CL 2016000397 A1 CL2016000397 A1 CL 2016000397A1 CL 2016000397 A CL2016000397 A CL 2016000397A CL 2016000397 A CL2016000397 A CL 2016000397A CL 2016000397 A1 CL2016000397 A1 CL 2016000397A1
Authority
CL
Chile
Prior art keywords
cancer treatment
tsa
tricotastin
tricostatin
aurka
Prior art date
Application number
CL2016000397A
Other languages
English (en)
Inventor
Polymeropoulos Mihael
William Licamele Louis
Lavedan Christian
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CL2016000397A1 publication Critical patent/CL2016000397A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Tratamiento contra el cancer que comprende la administración de TRICOTASTINA A TSA. El uso de tricostatina A TSA que es útil para preparar una composición farmacéutica que sirve para disminuir el nivel de expresión de la aurora quinasa A AURKA en un individuo.
CL2016000397A 2013-08-22 2016-02-22 Tratamiento contra el cáncer CL2016000397A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22

Publications (1)

Publication Number Publication Date
CL2016000397A1 true CL2016000397A1 (es) 2017-03-17

Family

ID=51794948

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000397A CL2016000397A1 (es) 2013-08-22 2016-02-22 Tratamiento contra el cáncer

Country Status (12)

Country Link
US (5) US20160199323A1 (es)
EP (2) EP3036007B1 (es)
JP (4) JP2016528297A (es)
KR (5) KR20170126018A (es)
CN (2) CN110585184A (es)
AU (4) AU2014308700A1 (es)
CA (1) CA2921036A1 (es)
CL (1) CL2016000397A1 (es)
EA (1) EA037667B1 (es)
ES (1) ES2755983T3 (es)
MX (1) MX2016002307A (es)
WO (1) WO2015027121A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528297A (ja) * 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療
WO2021016203A1 (en) * 2019-07-19 2021-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target
WO2023168201A1 (en) * 2022-03-01 2023-09-07 Vanda Pharmaceuticals Inc. Trichostatin a (tsa) sensitivity in the treatment of tumors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
CA1265431A (en) 1985-01-08 1990-02-06 Roderick John Macdonald Electrode device for flare stack ignitor
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
ATE468113T1 (de) * 2003-06-27 2010-06-15 Astellas Pharma Inc Therapeutisches mittel für ein weichteilsarkom
DK2537942T3 (en) 2004-05-21 2015-12-14 Trustees Of The University Of Arkansas System Board Of Use of genudtryksprofilering to predict survival in cancer patients
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
CA2652888A1 (en) 2006-05-26 2007-12-06 Celgene Corporation Methods and compositions using immunomodulatory compounds in combination therapy
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2013071247A1 (en) * 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene expression signatures of neoplasm responsiveness to theraphy
US9540382B2 (en) * 2012-06-04 2017-01-10 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
EP3036006B1 (en) 2013-08-22 2019-10-09 Vanda Pharmaceuticals Inc. Trichostatin a for multiple myeloma treatment
JP2016528297A (ja) * 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療

Also Published As

Publication number Publication date
JP2016528297A (ja) 2016-09-15
KR20210013343A (ko) 2021-02-03
EA201690445A1 (ru) 2016-06-30
KR102315528B1 (ko) 2021-10-21
KR20160033779A (ko) 2016-03-28
EP3616754A1 (en) 2020-03-04
AU2021261882B2 (en) 2022-04-14
AU2022202183B2 (en) 2023-09-28
WO2015027121A3 (en) 2015-05-14
ES2755983T3 (es) 2020-04-24
CN105579101A (zh) 2016-05-11
US11667718B2 (en) 2023-06-06
KR20170126018A (ko) 2017-11-15
MX2016002307A (es) 2016-06-15
US20160199323A1 (en) 2016-07-14
AU2014308700A1 (en) 2016-02-25
KR20230047203A (ko) 2023-04-06
US20210324093A1 (en) 2021-10-21
CA2921036A1 (en) 2015-02-26
AU2019261718A1 (en) 2019-11-28
US20230257471A1 (en) 2023-08-17
US20190211107A1 (en) 2019-07-11
WO2015027121A2 (en) 2015-02-26
US20180256522A1 (en) 2018-09-13
EP3036007B1 (en) 2019-10-09
EA037667B1 (ru) 2021-04-28
US10265282B2 (en) 2019-04-23
AU2022202183A1 (en) 2022-04-21
KR20210127821A (ko) 2021-10-22
US11078289B2 (en) 2021-08-03
JP2023088996A (ja) 2023-06-27
NZ716668A (en) 2021-02-26
AU2021261882A1 (en) 2021-12-02
CN110585184A (zh) 2019-12-20
JP2021105005A (ja) 2021-07-26
JP2019167351A (ja) 2019-10-03
EP3036007A2 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
CL2016000397A1 (es) Tratamiento contra el cáncer